Literature DB >> 34863818

Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue.

Zuwena A Richardson1, Claire Deleage2, Candani S A Tutuka3, Marzena Walkiewicz4, Perla M Del Río-Estrada5, Rachel D Pascoe1, Vanessa A Evans1, Gustavo Reyesteran5, Michael Gonzales6, Samuel Roberts-Thomson6, Mauricio González-Navarro5, Fernanda Torres-Ruiz5, Jacob D Estes7, Sharon R Lewin8, Paul U Cameron9.   

Abstract

The main barrier to a cure for HIV is the persistence of long-lived and proliferating latently infected CD4+ T-cells despite antiretroviral therapy (ART). Latency is well characterized in multiple CD4+ T-cell subsets, however, the contribution of regulatory T-cells (Tregs) expressing FoxP3 as well as immune checkpoints (ICs) PD-1 and CTLA-4 as targets for productive and latent HIV infection in people living with HIV on suppressive ART is less well defined. We used multiplex detection of HIV DNA and RNA with immunohistochemistry (mIHC) on formalin-fixed paraffin embedded (FFPE) cells to simultaneously detect HIV RNA and DNA and cellular markers. HIV DNA and RNA were detected by in situ hybridization (ISH) (RNA/DNAscope) and IHC was used to detect cellular markers (CD4, PD-1, FoxP3, and CTLA-4) by incorporating the tyramide system amplification (TSA) system. We evaluated latently infected cell lines, a primary cell model of HIV latency and excisional lymph node (LN) biopsies collected from people living with HIV (PLWH) on and off ART. We clearly detected infected cells that coexpressed HIV RNA and DNA (active replication) and DNA only (latently infected cells) in combination with IHC markers in the in vitro infection model as well as LN tissue from PLWH both on and off ART. Combining ISH targeting HIV RNA and DNA with IHC provides a platform to detect and quantify HIV persistence within cells identified by multiple markers in tissue samples from PLWH on ART or to study HIV latency.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIV latency; Immune checkpoints; Immunohistochemistry; In situ hybridization; Lymph nodes; Microscopy; RNAscope

Mesh:

Substances:

Year:  2021        PMID: 34863818      PMCID: PMC9036546          DOI: 10.1016/j.jim.2021.113198

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.287


  40 in total

1.  A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

Authors:  S Emiliani; C Van Lint; W Fischle; P Paras; M Ott; J Brady; E Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells.

Authors:  C Tacchetti; A Favre; L Moresco; P Meszaros; P Luzzi; M Truini; F Rizzo; C E Grossi; E Ciccone
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ.

Authors:  Joshua J Vasquez; Rajaa Hussien; Brandon Aguilar-Rodriguez; Henrik Junger; Dejan Dobi; Timothy J Henrich; Cassandra Thanh; Erica Gibson; Louise E Hogan; Joseph McCune; Peter W Hunt; Cheryl A Stoddart; Zoltan G Laszik
Journal:  J Histochem Cytochem       Date:  2018-02-20       Impact factor: 2.479

4.  PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals.

Authors:  Riddhima Banga; Francesco Andrea Procopio; Alessandra Noto; Georgios Pollakis; Matthias Cavassini; Khalid Ohmiti; Jean-Marc Corpataux; Laurence de Leval; Giuseppe Pantaleo; Matthieu Perreau
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

5.  CTLA-4+PD-1- Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques.

Authors:  Colleen S McGary; Claire Deleage; Justin Harper; Luca Micci; Susan P Ribeiro; Sara Paganini; Leticia Kuri-Cervantes; Clarisse Benne; Emily S Ryan; Robert Balderas; Sherrie Jean; Kirk Easley; Vincent Marconi; Guido Silvestri; Jacob D Estes; Rafick-Pierre Sekaly; Mirko Paiardini
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

6.  The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.

Authors:  Steven A Yukl; Amandeep K Shergill; Terence Ho; Maudi Killian; Valerie Girling; Lorrie Epling; Peilin Li; Lisa K Wong; Pierre Crouch; Steven G Deeks; Diane V Havlir; Kenneth McQuaid; Elizabeth Sinclair; Joseph K Wong
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

7.  Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo.

Authors:  Monika Hermankova; Janet D Siliciano; Yan Zhou; Daphne Monie; Karen Chadwick; Joseph B Margolick; Thomas C Quinn; Robert F Siliciano
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.

Authors:  Vanessa A Evans; Renée M van der Sluis; Ajantha Solomon; Ashanti Dantanarayana; Catriona McNeil; Roger Garsia; Sarah Palmer; Rémi Fromentin; Nicolas Chomont; Rafick-Pierre Sékaly; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

9.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.

Authors:  Nina N Hosmane; Kyungyoon J Kwon; Katherine M Bruner; Adam A Capoferri; Subul Beg; Daniel I S Rosenbloom; Brandon F Keele; Ya-Chi Ho; Janet D Siliciano; Robert F Siliciano
Journal:  J Exp Med       Date:  2017-03-24       Impact factor: 14.307

10.  Quantification of histopathological findings using a novel image analysis platform.

Authors:  Yasushi Horai; Mao Mizukawa; Hironobu Nishina; Satomi Nishikawa; Yuko Ono; Kana Takemoto; Nobuyuki Baba
Journal:  J Toxicol Pathol       Date:  2019-08-11       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.